{
    "symbol": "ZEAL",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-11 13:16:22",
    "content": " Thanks for the question and you very nicely summarized both what was part of the previous regulatory approval for dapiglutide and given the construct of our trials, obviously the statistical power for registration is tied to reduction in the volume of parenteral support, and secondarily, looking at similar proportion reduction in that parenteral support, but I think you also make a very important distinction which is the potential to reduce the number of days on parenteral support discontinuing parenteral support either on given day or a series of days will be critically important. Please ask your question. Please ask your question. Please ask your question. Please ask your question."
}